WEKO3
アイテム
Predictive Model for Adverse Events and Immune Response Based on the Production of Antibodies After the Second-Dose of the BNT162b2 mRNA Vaccine
https://repository.lib.tottori-u.ac.jp/records/4631
https://repository.lib.tottori-u.ac.jp/records/4631e7e0e2f1-8ed0-487e-a605-4a5a87b563b2
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
yam65(1)_63.pdf (1.1 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2022-03-09 | |||||
| タイトル | ||||||
| タイトル | Predictive Model for Adverse Events and Immune Response Based on the Production of Antibodies After the Second-Dose of the BNT162b2 mRNA Vaccine | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題 | adverse effect | |||||
| キーワード | ||||||
| 主題 | antibody | |||||
| キーワード | ||||||
| 主題 | BNT162b2 vaccine | |||||
| キーワード | ||||||
| 主題 | classification and regression tree | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | adverse effect | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | antibody | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | BNT162b2 vaccine | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | classification and regression tree | |||||
| 資源タイプ | ||||||
| 資源タイプ | journal article | |||||
| 著者 |
岡田, 晋一
× 岡田, 晋一× Tomita, Katsuyuki× 唐下, 泰一× 長谷川, 純一× 山崎, 章× Tomita, Katsuyuki× Inui, Genki× Ikeuchi, Tomoyuki× Touge, Hirokazu |
|||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Pediatrics, National Hospital Organization Yonago Medical Center | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Respiratory Medicine, National Hospital Organization Yonago Medical Center | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Respiratory Medicine, National Hospital Organization Yonago Medical Center | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Respiratory Medicine, National Hospital Organization Yonago Medical Center | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Respiratory Medicine, National Hospital Organization Yonago Medical Center | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Internal Medicine, National Hospital Organization Yonago Medical Center | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, School of Medicine, Faculty of Medicine, Tottori University | |||||
| 抄録 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Background: The BNT162b mRNA vaccine for coronavirus disease 2019, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), mimics the immune response to natural infection. Few studies have predicted the adverse effects (AEs) after the second-dose vaccination. We present a predictive model for AEs and immune response after the second-dose of the BNT162b mRNA vaccine. Methods: To predict AEs, 282 healthcare workers (HCWs) were enrolled in this prospective observational study. The classification and regression tree (CART) model was established, and its predictive efficacy was assessed. To predict immune response, 282 HCWs were included in the analysis. Moreover, the factors affected by anti-SARS-CoV-2 spike protein RBD antibody (s-IgG) were evaluated using serum samples collected 2 months after the second-dose vaccination. The s-IgG level was assessed using Lumipulse G1200. Multiple regression analyses were conducted to evaluate variables associated with anti-s-IgG titer levels. Results: The most common AEs after the second-dose vaccination were pain (87.6%), redness (17.0%) at the injection site, fatigue (68.8%), headache (53.5%), and fever (37.5%). Based on the CART model, headache after the first-dose vaccination and age < 30 years were identified as the first and second discriminators for predicting the headache after the second-dose vaccination, respectively. In the multiple linear regression model, anti-s-IgG titer levels were associated with age, female sex, and AEs including headache and induration at the injection site after the second-dose vaccination. Conclusion: Headache after the first-dose vaccination can be a predictor of headache after the second-dose vaccination, and AEs are indicators of immune response. | |||||
| 書誌情報 |
Yonago Acta Medica en : Yonago Acta Medica 巻 65, 号 1, p. 63-69, 発行日 2022-02-22 |
|||||
| 出版者 | ||||||
| 出版者 | Tottori University Medical Press | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 05135710 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00892882 | |||||
| DOI | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.33160/yam.2022.02.012 | |||||
| 権利 | ||||||
| 権利情報 | (C) 2022 Tottori University Medical Press. | |||||
| 情報源 | ||||||
| 関連名称 | Yonago Acta Medica. 2022, 65(1), 63-69. doi:10.33160/yam.2022.02.012 | |||||
| 関連サイト | ||||||
| 識別子タイプ | URI | |||||
| 関連識別子 | https://www.lib.tottori-u.ac.jp/yam/yam/yam65-1/65-1contents.html | |||||
| 関連名称 | https://www.lib.tottori-u.ac.jp/yam/yam/yam65-1/65-1contents.html | |||||
| 関連サイト | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.33160/yam.2022.02.012 | |||||
| 関連名称 | https://doi.org/10.33160/yam.2022.02.012 | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| EISSN | ||||||
| 値 | 13468049 | |||||
